Home » Industry Opposes Mandatory Prescriber Training for Opioids
Industry Opposes Mandatory Prescriber Training for Opioids
Drugmakers’ biggest concern about the impact of a classwide risk evaluation and mitigation strategy (REMS) for long-acting and extended-release
opioid pain drugs was that a requirement for mandatory physician training might cause physicians to stop prescribing the medications. Industry also expressed
concerns that a compulsory training program would shift prescribing to short-acting opioids and combination products not covered by the FDA’s draft
REMS, members of an industry working group told the FDA Friday.
Drug Industry Daily
Drug Industry Daily
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May